AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
REGENXBIO Enters Settlement Agreement to Resolve Patent Infringement Litigation
Sep 23, 2026•about 2 hours ago
Contract Type
settlement_agreement
RockvilleBiotechnologyHealth Care
Description
On September 23, 2026, REGENXBIO Inc. announced a Settlement Agreement with The Trustees of the University of Pennsylvania, Sarepta Therapeutics, Inc., and Catalent, Inc. The agreement resolves patent infringement litigation surrounding the manufacture and sale of SRP-9001. Sarepta will pay REGENXBIO $39.0 million as part of the settlement.
Company Information
Company
REGENXBIO
Location
Rockville, Maryland, United States
About
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
RockvilleBiotechnologyHealth Care